Detalhe da pesquisa
1.
Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation.
Ann Rheum Dis
; 82(5): 670-680, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36653124
2.
Myeloablative autologous haematopoietic stem cell transplantation resets the B cell repertoire to a more naïve state in patients with systemic sclerosis.
Ann Rheum Dis
; 82(3): 357-364, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36241361
3.
Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy.
Rheumatology (Oxford)
; 61(10): 4155-4162, 2022 10 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35108379
4.
Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial.
Am J Respir Crit Care Med
; 204(2): 209-221, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33651671
5.
Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.
N Engl J Med
; 378(1): 35-47, 2018 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29298160
6.
Machine learning predicts stem cell transplant response in severe scleroderma.
Ann Rheum Dis
; 79(12): 1608-1615, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32933919
7.
Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.
Ann Rheum Dis
; 78(1): 122-130, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30409830
8.
Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures.
Ann Rheum Dis
; 78(10): 1371-1378, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31391177
9.
Reply to Andréasson et al.: Multiple Manifestations of Systemic Sclerosis Affect Walk Distance.
Am J Respir Crit Care Med
; 204(3): 377-378, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34107229
10.
Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial.
Diabetologia
; 59(6): 1153-61, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27053235
11.
Myeloablation Followed by Hematopoietic Stem Cell Transplantation and Long-Term Normalization of Systemic Sclerosis Molecular Signatures.
Arthritis Rheumatol
; 2024 Mar 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38497141
12.
Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial.
Lancet Rheumatol
; 6(3): e168-e177, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38301682
13.
Clinical and Molecular Findings After Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal Data.
Arthritis Care Res (Hoboken)
; 75(2): 307-316, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34533286
14.
Large-Scale Characterization of Systemic Sclerosis Serum Protein Profile: Comparison to Peripheral Blood Cell Transcriptome and Correlations With Skin/Lung Fibrosis.
Arthritis Rheumatol
; 73(4): 660-670, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33131208
15.
Correlation Among Hypoglycemia, Glycemic Variability, and C-Peptide Preservation After Alefacept Therapy in Patients with Type 1 Diabetes Mellitus: Analysis of Data from the Immune Tolerance Network T1DAL Trial.
Clin Ther
; 38(6): 1327-1339, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27209482
16.
Safety and efficacy of HSCT for systemic sclerosis across clinical trials.
Nat Rev Rheumatol
; 16(11): 661, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32855553
17.
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.
J Clin Invest
; 125(8): 3285-96, 2015 Aug 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-26193635
18.
Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial.
Lancet Diabetes Endocrinol
; 1(4): 306-16, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24622416
19.
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.
Lancet Diabetes Endocrinol
; 1(4): 284-94, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24622414